search
Back to results

Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome (ISO-DRIVE)

Primary Purpose

Acute Respiratory Distress Syndrome, Mechanical Ventilation Complication, Sedation Complication

Status
Not yet recruiting
Phase
Phase 2
Locations
Study Type
Interventional
Intervention
Propofol
Isoflurane
Sponsored by
Guy's and St Thomas' NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Acute Respiratory Distress Syndrome

Eligibility Criteria

17 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Adult patients admitted to the Intensive Care Unit (ICU) ARDS Invasive mechanical ventilation (IMV) Spontaneous breathing in pressures support mode (PSV) for less than or equal to 48 hours Sedated with intravenous sedation (ie. propofol and / or midazolam and fentanyl or alternate short acting opioid) Anticipated to remain on IMV and PSV and with a stable sedation score for a further 24 hours without planned sedation interruption / spontaneous breathing trial or other significant change in the level of ventilator support Not receiving / anticipated to receive paralysis In supine position Exclusion Criteria: Personal or family history of malignant hyperpyrexia Known or suspected elevated intracranial pressure High dose vasopressors (ie. Noradrenaline > 0.3mcg/kg/min or equivalent) Contra-indication to oesophageal balloon (i.e. oesophageal / upper gastro-intestinal pathology) Pregnancy High dose oral sedatives (e.g. benzodiazepines) or opioids (e.g. oxycodone / oral morphine) which may affect respiratory drive

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Active Comparator

    Arm Label

    Conventional intravenous sedation

    Inhaled volatile sedation

    Arm Description

    Conventional intravenous sedation (e.g. propofol) with short acting opioid, titrated to a clinically prescribed sedation score. Period of observation will be 2 hours pre-cross over and 2 hours post cross over.

    Inhaled volatile sedation (Isoflurane) delivered via the AnaConDa device for a 6 hour period (2 hours washout of intravenous sedation / wash-in of volatile to achieve stable baseline, followed by 4 hours of observations at steady state) titrated to an equivalent sedation score. During this period opioid infusion should be maintained at baseline level unless clinical indication for titration of dose.

    Outcomes

    Primary Outcome Measures

    Respiratory drive (P0.1)
    Negative pressure in the first 100milliseconds of inspiration (P0.1) - Physiological parameter

    Secondary Outcome Measures

    Respiratory effort (Pmus)
    End expiratory occlusion pressure (Pmus) - Physiological parameter
    Respiratory effort (PMI)
    Pressure Muscle Index (PMI) - Physiological parameter
    Respiratory effort (Oesophageal pressure swings)
    Oesophageal pressure swings - Physiological parameter
    Gas exchange (PaO2:FiO2 ratio)
    Ratio of arterial partial pressure of oxygen to fractional inspired concentration of oxygen (PaO2:FiO2) - Physiological parameter
    Gas exchange (pulmonary shunt fraction (Qs/Qt))
    Pulmonary shunt fraction (Qs/Qt) - Physiological parameter
    Gas exchange ( ratio of ventilatory 'dead space' to tidal volume (Vd/Vt))
    ratio of ventilatory 'dead space' to tidal volume (Vd/Vt) - Physiological parameter
    Gas exchange (volume of carbon dioxide breathed out (VCO2))
    volume of carbon dioxide breathed out (VCO2) - Physiological parameter

    Full Information

    First Posted
    June 21, 2023
    Last Updated
    August 22, 2023
    Sponsor
    Guy's and St Thomas' NHS Foundation Trust
    Collaborators
    Sedana Medical
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT06014138
    Brief Title
    Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome
    Acronym
    ISO-DRIVE
    Official Title
    Effect of Volatile Sedation on Spontaneous Breathing During Mechanical Ventilation for Patients With the Acute Respiratory Distress Syndrome
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    August 2023
    Overall Recruitment Status
    Not yet recruiting
    Study Start Date
    September 30, 2023 (Anticipated)
    Primary Completion Date
    December 31, 2024 (Anticipated)
    Study Completion Date
    March 31, 2025 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor
    Name of the Sponsor
    Guy's and St Thomas' NHS Foundation Trust
    Collaborators
    Sedana Medical

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    This study will investigate how different types of routine sedation may affect patient's breathing whilst on a ventilator in the Intensive Care Unit (ICU). There are different approaches to sedation which may have advantages and disadvantages. During the study patients will receive both intravenous and inhaled volatile sedation (similar to anaesthetic 'gases' used for general anaesthesia) and the drive to breath, breathing efforts and function of the lung will be assessed.
    Detailed Description
    It is routine for patients to be sedated for their comfort and safety whilst on a ventilator in the Intensive Care Unit (ICU). Conventionally sedatives are given intravenously, however inhaled volatile sedation is becoming more popular. Inhaled sedation has recently been approved by the National Institute for Health and Clinical Excellence (NICE) in the United Kingdom (UK). Whilst being on a ventilator can be life-saving, it can cause potential problems. It is important that the patient interacts well with the ventilator and that their own breathing efforts are well regulated. There is evidence that inhaled sedation can specifically help the lungs when patients have the Acute Respiratory Distress Syndrome (ARDS) and in particular, inhaled sedation does not appear to suppress patient's own breathing as much as conventional sedation. Greater spontaneous breathing by the patient is usually positive but needs to be carefully understood to ensure it is not excessive or damaging to the patient's already injured lungs. This study of 20 patients is designed to carefully measure the impact of inhaled sedation on the patient's breathing and lung function, in comparison to intravenous sedation. Measurements will be taken whilst on intravenous sedation before the patient is switched to an equivalent level of inhaled sedation for six hours, when the measurements will be repeated. Finally, the patient will go back to their original intravenous sedation and the measurements taken again. This is called a 'cross-over' study and is a good way to evaluate the effect of the drug.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Acute Respiratory Distress Syndrome, Mechanical Ventilation Complication, Sedation Complication

    7. Study Design

    Primary Purpose
    Basic Science
    Study Phase
    Phase 2, Phase 3
    Interventional Study Model
    Crossover Assignment
    Model Description
    Prospective, cross-over trial design comparing intravenous versus inhaled volatile sedation
    Masking
    None (Open Label)
    Masking Description
    None, open label, physiological study
    Allocation
    Non-Randomized
    Enrollment
    20 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Conventional intravenous sedation
    Arm Type
    Active Comparator
    Arm Description
    Conventional intravenous sedation (e.g. propofol) with short acting opioid, titrated to a clinically prescribed sedation score. Period of observation will be 2 hours pre-cross over and 2 hours post cross over.
    Arm Title
    Inhaled volatile sedation
    Arm Type
    Active Comparator
    Arm Description
    Inhaled volatile sedation (Isoflurane) delivered via the AnaConDa device for a 6 hour period (2 hours washout of intravenous sedation / wash-in of volatile to achieve stable baseline, followed by 4 hours of observations at steady state) titrated to an equivalent sedation score. During this period opioid infusion should be maintained at baseline level unless clinical indication for titration of dose.
    Intervention Type
    Drug
    Intervention Name(s)
    Propofol
    Intervention Description
    Standard care, propofol sedation - 2 hour periods of observation before and after inhaled volatile sedation
    Intervention Type
    Drug
    Intervention Name(s)
    Isoflurane
    Intervention Description
    Inhaled volatile sedation for 6 hours - 2 hours wash in / wash out, followed by 4 hours of observations
    Primary Outcome Measure Information:
    Title
    Respiratory drive (P0.1)
    Description
    Negative pressure in the first 100milliseconds of inspiration (P0.1) - Physiological parameter
    Time Frame
    8 hours
    Secondary Outcome Measure Information:
    Title
    Respiratory effort (Pmus)
    Description
    End expiratory occlusion pressure (Pmus) - Physiological parameter
    Time Frame
    8 hours
    Title
    Respiratory effort (PMI)
    Description
    Pressure Muscle Index (PMI) - Physiological parameter
    Time Frame
    8 hours
    Title
    Respiratory effort (Oesophageal pressure swings)
    Description
    Oesophageal pressure swings - Physiological parameter
    Time Frame
    8 hours
    Title
    Gas exchange (PaO2:FiO2 ratio)
    Description
    Ratio of arterial partial pressure of oxygen to fractional inspired concentration of oxygen (PaO2:FiO2) - Physiological parameter
    Time Frame
    8 hours
    Title
    Gas exchange (pulmonary shunt fraction (Qs/Qt))
    Description
    Pulmonary shunt fraction (Qs/Qt) - Physiological parameter
    Time Frame
    8 hours
    Title
    Gas exchange ( ratio of ventilatory 'dead space' to tidal volume (Vd/Vt))
    Description
    ratio of ventilatory 'dead space' to tidal volume (Vd/Vt) - Physiological parameter
    Time Frame
    8 hours
    Title
    Gas exchange (volume of carbon dioxide breathed out (VCO2))
    Description
    volume of carbon dioxide breathed out (VCO2) - Physiological parameter
    Time Frame
    8 hours

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    17 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Adult patients admitted to the Intensive Care Unit (ICU) ARDS Invasive mechanical ventilation (IMV) Spontaneous breathing in pressures support mode (PSV) for less than or equal to 48 hours Sedated with intravenous sedation (ie. propofol and / or midazolam and fentanyl or alternate short acting opioid) Anticipated to remain on IMV and PSV and with a stable sedation score for a further 24 hours without planned sedation interruption / spontaneous breathing trial or other significant change in the level of ventilator support Not receiving / anticipated to receive paralysis In supine position Exclusion Criteria: Personal or family history of malignant hyperpyrexia Known or suspected elevated intracranial pressure High dose vasopressors (ie. Noradrenaline > 0.3mcg/kg/min or equivalent) Contra-indication to oesophageal balloon (i.e. oesophageal / upper gastro-intestinal pathology) Pregnancy High dose oral sedatives (e.g. benzodiazepines) or opioids (e.g. oxycodone / oral morphine) which may affect respiratory drive
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Guy Glover
    Phone
    00447879696250
    Email
    guy.glover@gstt.nhs.uk
    First Name & Middle Initial & Last Name or Official Title & Degree
    Gill Radcliffe
    Phone
    02071887188
    Email
    gillian.radcliffe@gstt.nhs.uk
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Guy Glover
    Organizational Affiliation
    Guy's and St Thomas' NHS Trust
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Volatile Sedation for Patients With the Acute Respiratory Distress Syndrome

    We'll reach out to this number within 24 hrs